3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
17
Triple Negative Breast Neoplasms
9
Urinary Bladder Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplastic Cells, Circulating
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Hormone Receptor Positive HER-2 Negative Breast Cancer
1
HR-positive,HER2-negative Breast Cancer
1
HR+/HER2- Breast Cancer
1
HER2-negative Early Breast Cancer
1
HER2-negative Breast Cancer
1
HER2 Positive Early Breast Cancer
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Adenoid Cystic
1
Interventions
Blood Specimen Collection
5
Liquid Biopsy
2
Folfox protocol
2
Carboplatin
2
pertuzumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Sevoflurane
1
Radiotherapy, Adjuvant
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Mastectomy, Segmental
1
Gemcitabine
1
Fluorouracil
1
Epirubicin
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
Colonography, Computed Tomographic
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Capecitabine
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplastic Cells, Circulating
×
Epirubicin
×
Clear all
NCT04771871
2026-05-07
TARMAC
University College Hospital, Ibadan
Phase 2
Recruiting
42 enrolled